Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. is advancing its lead drug candidate, PrimeC, for ALS treatment with an upcoming FDA meeting to finalize its Phase 3 trial design and a planned submission to Health Canada by Q2 2025. The company highlights PrimeC’s promising trial results, showing significant reduction in ALS progression and improved survival rates, suggesting a strong potential market in Canada. This strategic move positions NeuroSense as a key player in addressing the urgent unmet needs of ALS patients.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
